DeepMed Research

Western History Collection

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1890-01-01

Employees: 10K

Market Cap: -

Website: http://www.ou.edu

Clinical Trials

Effects of Naproxen on Physical Performance

Phase 4

Terminated

Conditions: Healthy

First Posted Date: 2006-12-13

Last Posted Date: 2007-10-11

Lead Sponsor: University of Oklahoma

Target Recruit Count: 40

Registration Number: NCT00410995

Locations: 🇺🇸
Family Practice - CMT, Tulsa, Oklahoma, United States

Phacoemulsification Sleeves

Completed

Conditions: Cataract

Interventions: Procedure: Phacoemulsification Sleeves surgery
Procedure: Phacoemulsification Sleeves
Procedure: Phacoemulsification Sleeve surgery

First Posted Date: 2006-02-09

Last Posted Date: 2023-12-15

Lead Sponsor: University of Oklahoma

Target Recruit Count: 44

Registration Number: NCT00289068

Locations: 🇺🇸
Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States

Autoimmune Dysregulation in Pigmentary Glaucoma

Not Applicable

Completed

Conditions: Primary Open Angle Glaucoma
Pigmentary Glaucoma
Cataract

First Posted Date: 2006-01-23

Last Posted Date: 2023-12-15

Lead Sponsor: University of Oklahoma

Target Recruit Count: 23

Registration Number: NCT00280345

Locations: 🇺🇸
Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States

Management of Superficial Thrombophlebitis

Phase 4

Completed

Conditions: Superficial Thrombophlebitis
Upper Extremity Superficial Thrombophlebitis
Lower Extremity Superficial Thrombophlebitis

Interventions: Drug: Dalteparin sodium injection

First Posted Date: 2005-12-12

Last Posted Date: 2013-11-18

Lead Sponsor: University of Oklahoma

Target Recruit Count: 72

Registration Number: NCT00264381

Locations: 🇺🇸
Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, United States
🇺🇸
University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States

Treatment of Upper Extremity Deep-Vein Thrombosis

Phase 4

Completed

Conditions: Deep-Vein Thrombosis

Interventions: Drug: Dalteparin sodium injection
Drug: Warfarin

First Posted Date: 2005-10-28

Last Posted Date: 2013-02-21

Lead Sponsor: University of Oklahoma

Target Recruit Count: 67

Registration Number: NCT00245856

Locations: 🇺🇸
Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, United States
🇺🇸
University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States

Effect of Cinnamon on Glucose and Lipid Levels in Non-Insulin Dependent Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus, Adult Onset

Interventions: Drug: Cinnamon or placebo 500 mg capsule twice daily

First Posted Date: 2005-10-12

Last Posted Date: 2008-09-22

Lead Sponsor: University of Oklahoma

Target Recruit Count: 85

Registration Number: NCT00237640

Locations: 🇺🇸
General Clinical Research Center, Oklahoma City, Oklahoma, United States

Triamcinolone vs. Laser for Diabetic Macular Edema

Not Applicable

Completed

Conditions: DIABETIC MACULAR EDEMA

Interventions: Procedure: laser
Drug: Triamcinolone acetonide

First Posted Date: 2005-09-30

Last Posted Date: 2023-12-28

Lead Sponsor: University of Oklahoma

Target Recruit Count: 11

Registration Number: NCT00229931

Locations: 🇺🇸
Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States

Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease

Phase 4

Completed

Conditions: Coronary Artery Disease

First Posted Date: 2005-09-29

Last Posted Date: 2008-09-22

Lead Sponsor: University of Oklahoma

Target Recruit Count: 25

Registration Number: NCT00229528

Locations: 🇺🇸
The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

Fluoroscopy Guided Femoral Arterial Access

Not Applicable

Completed

Conditions: Vascular Access

Interventions: Procedure: Active Comparator
Procedure: Fluoroscopy

First Posted Date: 2005-09-22

Last Posted Date: 2012-03-28

Lead Sponsor: University of Oklahoma

Target Recruit Count: 990

Registration Number: NCT00222430

Locations: 🇺🇸
University of Oklahoma Medical Center, Oklahoma City, Oklahoma, United States
🇺🇸
Veterans Affairs Medical Center, Oklahoma City, Oklahoma, United States

Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: bevacizumab
Drug: gemcitabine
Drug: oxaliplatin

First Posted Date: 2005-09-22

Last Posted Date: 2008-07-09

Lead Sponsor: University of Oklahoma

Target Recruit Count: 50

Registration Number: NCT00222469

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy